Truman J. Milling, MD, Alex C. Spyropoulos, MD

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Usefulness of Outpatient Bleeding Risk Index to Predict Bleeding Complications in Patients With Long-term Oral Anticoagulation Undergoing Coronary Stenting

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Heather C. Brod, MA, Stanley Lemeshow, PhD, Philip F. Binkley, MD, MPH

Bleeding Toes in Diabetic Neuropathy

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Richard V. Milani, MD, Carl J. Lavie, MD, Robert M

The Systolic Blood Pressure Difference Between Arms and Cardiovascular Disease in the Framingham Heart Study Ido Weinberg, Philimon Gona, Christopher.

Sleep Apnea and Risk of Deep Vein Thrombosis: A Non-randomized, Pair-matched Cohort Study Kun-Ta Chou, MD, Chin-Chou Huang, MD, Yuh-Min Chen, MD, PhD,

Aruna D. Pradhan, MD, Nader Rifai, PhD, Julie E. Buring, ScD, Paul M

Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc

Niv Ad, MD, Linda Henry, PhD, RN, Deborah J. Shuman, BS, Sari D

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Prognostic Value of Low Blood Glucose at the Presentation of E

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Pyogenic Liver Abscess as the Initial Manifestation of Underlying Hepatocellular Carcinoma Yi-Tsung Lin, MD, Chia-Jen Liu, MD, Tzeng-Ji Chen, MD, Te-Li.

Prognostic Importance of Low Admission Serum Creatinine Concentration for Mortality in Hospitalized Patients Charat Thongprayoon, MD, Wisit Cheungpasitporn,

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Body Mass Index and Mortality in Acute Myocardial Infarction Patients

Epidemiology of Myelodysplastic Syndromes

Trend in Mortality after Stroke with Atrial Fibrillation

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study Jian Shan, MD, Lili Zhang, MD, MSc,

Obstructive Sleep Apnea as a Risk Factor for Type 2 Diabetes

Peter K. Wung, MD, Janet T. Holbrook, PhD, MPH, Gary S

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Laura Boucai, MD, MS, William N

A new lease on life for patients with Duchenne muscular dystrophy in Japan Fumihiko Yasuma, MD, Masaaki Konagaya, MD, Motoko Sakai, MD, Satoshi Kuru,

Apurva O. Badheka, MD, Ankit Rathod, MD, Mohammad A

Aortic valve replacement in patients with mild or moderate aortic stenosis and coronary bypass surgery Jeremy J. Pereira, MB, Krzysztof Balaban, MD,

Family History for Venous Thromboembolism and the Risk for Recurrence

The Reply The American Journal of Medicine

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Gout in African Americans

Matthew W. Parker, MD, Murray A. Mittleman, MD, DrPH, Carol A

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

The Obesity Paradox and Weight Loss

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Repeated Hemoglobin A1C Ordering in the VA Health System

The Reply The American Journal of Medicine

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

MATCH Results: Implications for the Internist

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

Insomnia in the Elderly: Cause, Approach, and Treatment

To Reduce Stroke with PFO Closure, Respect the Shunt

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

National Trends in Ambulatory Oral Anticoagulant Use

Heather C. Brod, MA, Stanley Lemeshow, PhD, Philip F. Binkley, MD, MPH

The American Journal of Medicine

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

The American Journal of Medicine

Plasma Lactescence in Acute Pancreatitis

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Barriers to Adult Immunization

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Falls in Older Adults: Risk Assessment, Management and Prevention

Longer Lengths of Stay and Higher Risk of Mortality among Inpatients of Physicians with More Years in Practice William N. Southern, MD, MS, Eran Y. Bellin,

Toward a More Responsible News Media

David Tian, MD, Ram Jhingan Mohan, MD, Gary Stallings, MD

Significance of Comorbid Psychological Stress and Depression on Outcomes After Cardiac Rehabilitation Sergey Kachur, MD, Arthur R. Menezes, MD, Alban.

Presentation transcript:

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed Truman J. Milling, MD, Alex C. Spyropoulos, MD The American Journal of Medicine Volume 129, Issue 11, Pages S54-S63 (November 2016) DOI: 10.1016/j.amjmed.2016.06.006 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure Unmatched survival and event rates in atrial fibrillation patients: analyzing oral anticoagulant resumption status. (Reproduced with permission from reference27) Unmatched Kaplan-Meier survival curves, ischemic, and hemorrhagic event rates in atrial fibrillation (AF) patients with and without oral anticoagulant (OAC) resumption. (A) Kaplan-Meier survival rates of patients with AF with and without OAC resumption from index-intracranial hemorrhage (ICH) until 1-year follow-up, analyzed by log-rank, Breslow, and Tarone–Ware testing, with corresponding P values. (B) Incidence rates of new ischemic events over the 1-year follow-up period in patients with and without OAC resumption. (C) Incidence rates of hemorrhagic events over the 1-year follow-up period in patients with and without OAC resumption. Numbers for patients at risk apply to parts A–C. One year after OAC-related ICH 8.2% (n = 9/110) of resumed patients vs 37.5% (n = 171/456) of patients without OAC resumption had died (P < .001). The crude incidence of bleeding events was not significantly different among AF patients with and without OAC resumption (OAC resumed: 7.3% [n = 8/110] vs 5.7% [n = 26/456] nonresumed patients; P = .532), the incidence of new ischemic events was significantly increased in patients without OAC resumption (5.4% [n = 6/110] vs 14.9% [n = 68/456]; P = .008). The American Journal of Medicine 2016 129, S54-S63DOI: (10.1016/j.amjmed.2016.06.006) Copyright © 2016 Elsevier Inc. Terms and Conditions